Clinical Trials Directory

Trials / Completed

CompletedNCT06002893

The Antihypercholestrolemic Effect of a Combined Nutritional Supplementation of Standardized Extracts of Amla, Walnut, Red Yeast Rice and Olive

The Antihypercholestrolemic Pharmacological Effect of a Combined Supplement of Amla Fruit, Walnut Leaves, Red Yeast Rice, and Olive Fruit Extracts Leads to Improvement in Circulatory Levels of LDL-C and Remnant Cholesterol

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
221 (actual)
Sponsor
Liaquat University of Medical & Health Sciences · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

Nutraceutical lipid-lowering interventions are becoming increasingly popular, particularly among patients who are intolerant or refractory to prescription statins, or who desire alternative non-conventional pharmacological treatment to manage their dyslipidaemia, whether they previously experienced statin intolerance or not. A growing body of preclinical and clinical evidence suggest that the amla (Emblica officinalis) red yeast rice (RYR), olive and walnut leaf extracts posses consideable hpolipidaemic pharmacological effects.

Detailed description

The present exploratory study aimed to assess the safety, efficacy, and patient's satisfaction of a combined supplementation of amla, red yeast rice, olive, and walnut leaf extracts (Cholesfytol NG®) on total cholesterol (TC), low-density lipoprotein - cholesterol (LDL-C), high-density lipoprotein - cholesterol (HDL-C), non-high-density lipoprotein - cholesterol (non-HDL-C), remnant cholesterol (RC) and triglycerides (TG) in hyperlipidaemic patients.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCholesfytol NG®) supplementGeneral Practitioner (GP) prescribed oral Cholesfytol NG®) supplement

Timeline

Start date
2020-03-19
Primary completion
2022-03-31
Completion
2023-07-31
First posted
2023-08-21
Last updated
2023-08-21

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06002893. Inclusion in this directory is not an endorsement.